ExpressCells is a private biotechnology company based in Philadelphia, PA. Our propriety genome editing technology, in combination with CRISPR/Cas9, allows the company to create advanced, knock-in cell lines to enhance drug discovery and other biological research, and shorten the time for delivery of knock-in cell lines by 75% relative to current technologies. Our genetic engineering technology was invented at the Temple University School of Pharmacy by Oscar Perez-Leal, MD. ExpressCells holds a global, exclusive license on this technology. For more information, visit www.xpresscells.com.